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A B S T R A C T
Flupirtine (FLU) is a non-opioid analgesic drug, with no antipyretic or anti-inflammatory effects, used
in the treatment of a wide range of pain states in human beings. It does not induce the side effects as-
sociated with the classical drugs used as pain relievers. The aim of this study was to evaluate the
pharmacokinetic profiles of FLU after IV and PO administration in healthy horses. Six mixed breed adult
mares were randomly assigned to two treatment groups using an open, single-dose, two-treatment, two-
phase, paired, cross-over design (2 × 2 Latin-square). Group 1 (n = 3) received a single dose of 1 mg/kg
of FLU injected IV into the jugular vein. Group 2 (n = 3) received FLU (5 mg/kg) via nasogastric tube. The
animals then swapped groups after a 1-week wash-out period and the doses were repeated. Blood samples
(5 mL) were collected at 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 24, 36 and 48 h and plasma was then analysed
by a validated HPLC method.
Some mild and transient adverse effects (that spontaneously resolved within 5 min) were observed
in 2/6 animals after IV administration. No adverse effects were noticed in the PO administration group.
After IV and PO administrations, FLU was detectable in plasma for up to 36 h. The mean elimination half-
life was longer after PO (10.27 h) than after IV (3.02 h) administration. The oral bioavailability was
71.4 ± 33.1%. After compartmental simulation/modelling, an oral dose of 2.6 mg/kg was calculated to give
Cmax and AUC values in horses similar to those reported in humans after a clinical dose administration
with a theoretical FLU effective plasma concentration of 187 ng/mL. These findings may form the basis
for further studies concerning this active ingredient in equine medicine.
© 2015 Published by Elsevier Ltd.
Introduction
Flupirtine (FLU) is an aminopyridine drug (ethyl {2-amino-6-
[(4-fluorobenzyl)amino]pyridin-3-yl}carbamate) approved in Europe
in 1984 for the treatment of pain (Kumar et al., 2013). FLU is a cen-
trally acting analgesic with a mechanism of action unlike that of
opiates and non-steroidal anti-inflammatory drugs (NSAIDs); it is
active with a favourable tolerability, and has no antipyretic or anti-
inflammatory effects (Devulder, 2010). FLU was the first drug to be
recognised in the class of ‘Selective Neuronal Potassium Channel
Openers’ (SNEPCOs) (Kornhuber et al., 1999).
FLU interacts with the G-protein-regulated, Inwardly Rectify-
ing K+ channels (GIRKs), a novel family of K+ channels (distinct from
the voltage-dependent ones) that are regulated by neurotransmit-
ters and expressed in different parts of the brain. FLU activates GIRKs
and stabilizes the membrane resting potential by activating KCNQ
potassium channels so generating a neuronal hyperpolarizing current
(M-current); the increased M-current results in decreased neuro-
nal excitability (Kolosov et al., 2012). In addition, FLU inhibits the
NMDA receptor indirectly by acting as an oxidizing agent at the redox
site of the NMDA receptor, maintaining the Mg2+ block on the NMDA
receptor (Devulder, 2010).
FLU can be useful in the treatment of a wide range of pain states
in humans. In line with its mechanism of action reducing neuro-
nal hyperexcitability, it has proven useful in conditions involving
neuronal hyperexcitability such as chronic pain (non-malignant and
malignant), migraine and neurogenic pain (Luben et al., 1994; Wörz
et al., 1996; Mueller-Schwefe, 2003; Ringe et al., 2003; Li et al., 2008;
Szelenyi, 2013). Furthermore, its effect as a muscle relaxant repre-
sents and adds value in painful conditions associated with increased
muscle tension, such as musculoskeletal back pain, myofascial pain
and tension headaches (Worz, 1991; Wörz et al., 1995, 1996;
Banerjee et al., 2012; Kumar et al., 2013). FLU has also been shown
to be beneficial in the short-term treatment of acute to moderate
pain, such as post-operative pain, trauma and dysmenorrhoea
(Heusinger, 1987).
The approved indications for FLU differ between countries but
mainly include the clinical management of musculoskeletal pain,
post-operative pain, headache, dysmenorrhoea, neuralgia and
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neuritis, post-traumatic pain (trauma and chemical burns) and pain
associated with cancer (Devulder, 2010; Harish et al., 2012). It has
not been used to its full potential as an analgesic in the first decade
of the 21st century, but there has recently been a resurgence in FLU
use after discovery of its powerful additive effects when used with
opioids (Goodchild et al., 2008; Capuano et al., 2011; Kolosov et al.,
2012; Lee et al., 2015) in addition to its properties when used alone
(Wilhelmi, 2013).
While there is a substantial body of evidence on the efficacy of
FLU in humans, only a small number of studies on the analgesic effect
of FLU in laboratory animals are to be found in the literature (Gordon
et al., 1987; Schwarz et al., 1995; Nielsen et al., 2004) and its phar-
macokinetic profiles in cats (De Vito et al., 2014a) and dogs (De Vito
et al., 2014b) have been recently described. Advanced studies (phase
III) in dogs and horses are ongoing in the USA, and although data
are not yet available, FLU is likely to be launched on the veteri-
nary market in the near future.1 The aim of the present study was
to evaluate the pharmacokinetic profiles of FLU after IV and PO ad-
ministration in healthy horses.
Materials and methods
Chemicals and reagents
Pure FLU maleate salt and the Internal Standard trazodone (IS) powder (both
>99.0% purity) were supplied by Sigma-Aldrich. Acetonitrile (ACN; HPLC grade), meth-
anol (MeOH), dichloromethane (CH2Cl2) and ethyl acetate (AcOEt) were purchased
fromMerck. Ammonium acetate (AcONH4) was purchased from Carlo Erba. Deionised
water was produced by a Milli-Q Water System (Millipore). All other reagents and
materials were of analytical grade and supplied from commercial sources. The LC
mobile phase was filtered through 0.2 μm cellulose acetate membrane filters (Sar-
torius Stedim Biotech) with a solvent filtration apparatus.
Animal and experimental design
The subjects were six racehorse mares (Italian trotters), aged 9–13 years and
weighing 480–590 kg. The horses were determined to be clinically healthy based
on physical examination, serum chemistry and haematological analyses. Animals were
evaluated daily (for 1week) for visible adverse effects by specialized personnel. Animal
care and handling was performed according to the provision of the EC council Di-
rective 86/609 EEC and also according to Institutional Animal Care and Use directives
issued by the Animal Welfare Committee of the University of Pisa, which approved
the study protocol.
Horses were randomly assigned to two treatment groups (six slips of paper
marked with the numbers 1 to 6 in a box), using an open, single-dose, two-
treatment, two-phase, paired, cross-over design (2 × 2 Latin-square). All subjects were
fasted for 12 h overnight before each experiment. During the first phase each horse
in group 1 (n = 3) received a single dose of 1 mg/kg of FLU (Katadolon vials con-
taining 164.5 mg/3 mL FLU D-gluconate [corresponding to 100 mg FLU/3 mL]; AWD
Pharma) injected IV into an indwelling catheter previously inserted in the right jugular
vein (flow rate 3 mL/min). Group 2 (n = 3) received a dose of 5 mg/kg orally (Efiret
100 mg hard capsules containing FLU maleate; Meda Pharma). The oral formula-
tion of FLU was given to all animals via nasogastric tube and consisted of capsules
in 500 mL of distilled water. After administration, the nasogastric tube was rinsed
with 500 mL of distilled water to ensure complete delivery of the drug into the
stomach.
A 1-week wash out period was observed between the phases, then the groups
were rotated and the experiment was repeated. The left jugular vein was catheterised
to facilitate blood sampling. Blood samples (5 mL) were collected at 0.083, 0.25, 0.5,
0.75, 1, 1.5, 2, 4, 6, 8, 10, 24, 36 and 48 h after administration of FLU and placed in
collection tubes containing lithium heparin. Samples were immediately centri-
fuged at 2000 g (10 min), and the harvested plasma was stored at −20 °C until use
within 30 days from collection.
High performance liquid chromatography
The analytical method was based on a previous method validated in dog plasma
(De Vito et al., 2014b). In brief, the HPLC system was an LC Jasco consisting of qua-
ternary gradient system (PU 980) and an inline multilambda fluorescence detector
(FP 1520). The chromatographic separation assay was performed with a Luna C18(2)
analytical column (250mm × 4.6mm inner diameter, 5 μm particle size; Phenomenex)
preceded by a guard column with the same stationary phase (C18(2); Phenomenex).
The system was maintained at 25 °C. The mobile phase consisted of ACN:AcONH4
(20mM) solution, pH 6.8 (60:40, v/v) at a flow rate of 1mL/min. Excitation and emis-
sion wavelengths were set at 323 and 370 nm, respectively. The elution of the
substances was carried out in isocratic mode.
Sample extraction
The procedure was performed in a 15 mL polypropylene vial. A 500 μL aliquot
of plasmawas added to 100 μL of IS (100 μg/mL) and vortexed for 60 s. Four millilitres
of AcOEt:CH2Cl2 (7:3 v/v) were added, then the sample was vortexed (30 s), shaken
(100 osc/min, 10min) and centrifuged at 3000 g for 10min at 10 °C. Three millilitres
of the supernatant were collected in a separate clean vial. The organic phase was
evaporated under a gentle stream of nitrogen at 40 °C and reconstituted with 500 μL
of the mobile phase. Twenty microlitres of this latter solution were injected onto
the HPLC-FL.
Pharmacokinetic evaluation
FLU plasma concentration vs. time curves were modelled for each subject using
a mono- or two-compartment open model (Gibaldi and Perrier, 1982). Compari-
son between competing models was made using the residual plots, visual inspection
of the goodness of fit curves and the Akaike’s information criterion. The pharma-
cokinetic calculations were carried out using WinNonLin v 5.3.1 (Pharsight). The PO
bioavailability was calculated from the ratio of the areas under the plasma FLU con-
centration curve after PO and IV administration, respectively, indexed to their
respective dose:
F AUC Dose AUC DosePO IV IV PO%( ) = ×( ) ×( ) ×100
Based on the PK analysis of pooled data, computer simulations (WinNonlin 5.3.1)
were performed to calculate the oral dose that should be administered to horses
in order to achieve the values of Cmax (773 ng/mL) and AUC (6070 h ng/mL) re-
ported in humans after oral administration of a clinical dose (Abrams et al., 1988).
These calculations were based on the assumptions that the plasma protein binding
is the same in humans and horses and that the effective plasma concentrations are
of the same order of magnitude for the two species. When the theoretical dosage
regimen in horses (a PK/PD hybrid variable) was evaluated, the relative effective plasma
drug concentration (assumed at the steady state) was calculated according the fol-
lowing formulae (Toutain, 2009):
EC ED Bioavailability Clearance= ×( )
where EC is the average effective target plasma concentration needed to obtain the
desired clinical response, ED is the dose per dosing interval (amount/time),
bioavailability is the extent of systemic bioavailability (a factor between 0 and 1),
and clearance is the plasma clearance expressed for the given dosing interval.
Statistical analysis
Pharmacokinetic variables were evaluated using Student’s t test to determine
statistically significant differences between the treatment groups. Both pharmaco-
kinetic parameters and FLU plasma concentrations are presented as means ± standard
deviation (normality tested by Shapiro–Wilk test). All analyses were conducted using
GraphPad InStat (GraphPad Software). In all experiments, differences were consid-
ered significant if P < 0.05.
Results
TheHPLCmethodwas re-validated using horse plasma. Briefly, FLU
was linear (r2 > 0.99) in the range 10–1500 ng/mL. When samples ex-
ceeded the upper limit of the range, they were re-analysed after
appropriate dilution. The intra-day repeatability wasmeasured as co-
efficient of variation and was <5.3%, whereas accuracy, measured as
closeness to the concentration added on the same replicates,was <6.2%.
Immediately after IV injectionof thedrug, 2/6horses showedadverse
effects includingmuscle twitching, head shaking and agitation but they
resolved spontaneously within 5min. No behavioural changes or al-
terations in health parameters (heart rate, rectal temperature and
intestinal sounds) were observed in the remaining animals during or
up to 7 days after the study. Health parameters and behaviour were
evaluated once a day and were found to be normal.
A bi-compartmental model best fitted the plasma concentra-
tions after IV and PO administrations in all the six horses. A two-
compartment model with bolus input and first-order output, with
micro-constants as primary parameters was used for the IV admin-
istration while a first-order input, first-order output, no lag time1 See http://www.kindredbio.com/#!pipeline/c1ktj (accessed 10 August 2015).
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with micro-constants as primary parameters was used for the PO
administration. The average plasma concentration vs. time curves
after both the administrations are reported in Fig. 1.
FLUwas detectable in plasma up to 36 h, and at 48 h the drug con-
centrations dropped down the LOQ of the method. After oral
administration (5mg/kg), the FLU plasma concentrations were quite
variable, butwere detectable over the same range of time. The average
Cmax (1639ng/mL)was shown at a Tmax of 2.16h. The oral bioavailability
(F%) was 71.4 ± 33.1%. The half-life of elimination (Beta_HL) value was
3 ×higher in the PO compared to the IV group. Themean values of both
clearance and volume of distribution were significantly different
between the groups including when normalized for dose and F%. The
complete pharmacokinetic parameters are reported in Table 1.
After pharmacokinetic simulation of PO multiple dosing, it was
found that if the drug is administered once every 24 h the steady
state would be achieved after the second administration. The oral
dose that theoretically should be administered to horses in order
to achieve similar Cmax and AUC values to those reported with clin-
ical doses in humans is 2.6 mg/kg (Fig. 2). When the theoretical
effective drug plasma concentration (EC) was calculated from the
relevant parameters ED, clearance and bioavailability, it was shown
that the theoretical analgesic effect should be achieved at drug
plasma concentrations > 187 ng/mL. The average pharmacokinetic
profile indicated that this value is exceeded for over 9 h and 15 h
following administration (Fig. 2) of 2.6 and 5 mg/kg of FLU,
respectively.
Discussion
FLU is a centrally acting, non-opioid analgesic that is available
in a number of European countries for the treatment of a variety
of pain states (Devulder, 2010). The therapeutic benefits seen with
FLU relate to its unique pharmacological properties. Recently its po-
tential for use in veterinary medicine has been explored (Giorgi and
Owen, 2012). Preclinical studies showed that FLU was more potent
than paracetamol and as potent as pentazocine in the electro-
stimulated pain test in mice (Nickel, 1987) and significantly pro-
longed the latency of the tail-flick test in rats (Szelenyi et al., 1989).
Furthermore, it produced an efficacy profile superior to that of
tramadol for cancer-associated pain (Luben et al., 1994; Kolosov et al.,
2012). FLU also produced a significant increase in morphine anti-
nociception when the two drugs were administered in combination
in different rat models of pain (Goodchild et al., 2008; Capuano et al.,
2011). If the sparing opioid effect is also evident in horses, this active
ingredient could play an important role in multimodal analgesic
therapy in order to avoid moderately high regimens of opioids.
Allometric scaling is an approach for dosage selection that can
be used in the absence of either species-specific pharmacokinetic
data or prior drug experience in the target species (Hunter, 2010).
In the present study, an approach based on data extrapolated from
humans rather than an allometric calculation of the dose was pre-
ferred. Both the approaches share the assumption that species
differences in pharmacodynamics are clinically negligible. The oral
dose administered in the present study (5 mg/kg) was about
3 × higher than the minimum dose reported in human clinical prac-
tice (100 mg/subject/day). However, it was still within the
recommended human clinical range (100–400 mg/subject/day;
Devulder, 2010).
Fig. 1. Mean flupirtine plasma concentration (semi-logarithmic scale) vs. time curves
following PO (5mg/kg) (–●–) and IV (–○–) (1mg/kg) administrations in healthy horses
(n = 6). Bars represent the standard deviation of the mean.
Table 1
Relevant pharmacokinetic parameters of flupirtine after IV (1mg/kg) and PO (5mg/kg)
administrations in healthy horses (n = 6).
Parameters Units IV PO
Mean SD Mean SD
AUC h*ng/mL 4003 1193 13,211 4914
K01_HL h / / 1.38 0.62
K10_HL h 0.84 0.44 2.26 0.26
Alpha 1/h 8.19 6.44 0.60 0.31
Beta 1/h 0.27 0.12 0.07 0.03
Alpha_HL h 0.12 0.06 1.41 0.65
Beta_HL h 3.02 1.30 10.27 3.27
Cmax ng/mL 3706 1119 1,512 643
Tmax h / / 2.16 0.85
CLa mL/h/kg 269.7 83.58 411 107.9
V2 mL/kg 656.8 121.9 / /
V1 mL/kg 289.3 80.87 / /
K01 1/h / / 0.61 0.30
K10 1/h 1.06 0.66 0.31 0.04
K12 1/h 5.26 4.68 0.21 0.24
K21 1/h 2.13 1.40 0.15 0.10
F% % 71.4 33.1
AUC, area under the plasma concentration – time curve; K01_HL, half-life of the ab-
sorption phase; K10_HL, half-life of the elimination phase; Alpha, rate constant
associatedwith distribution; Beta, rate constant associatedwith elimination; Alpha_HL,
distribution half-life; Beta_HL, elimination half-life; Cmax, peak plasma concentra-
tion; Tmax, time of peak; CL, clearance; V2, volume of compartment 2; V1, volume
of compartment 1; K01, absorption rate; K10, elimination rate from compartment
1; K12, rate of movement from compartment 1 to 2; K21, rate of movement from
compartment 2 to 1; F%, bioavailability.




















Fig. 2. Mean plasma concentration vs. time curves for flupirtine following a simu-
lated POmultiple dose rate at 5mg/kg/day (dotted line) and a simulated POmultiple
dose rate at 2.6 mg/kg/day (solid line). The dashed line represents the theoretical
effective concentration (to be confirmed with experimental data).
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The rationale for dose selection of 5 mg/kg was based on earlier
preclinical studies in dogs and cats. The ED50 of FLU after oral ad-
ministration in the electrical tooth pulp stimulation test in dogs and
cats was 3.5mg/kg (Nickel, 1987) and 3mg/kg (Gordon et al., 1987),
respectively. Additionally, recent pharmacokinetic studies carried
out with this dose regimen did not show any adverse effects after
oral administration (De Vito et al., 2014a and b).
On the other hand as an IV dose, administration of 5 mg/kg FLU
produced some adverse effects such as tremors, vomiting and ag-
itation in dogs (De Vito et al., 2014b). In the present study the IV
dose was reduced to 1 mg/kg to minimise potential adverse effects.
Although the dose was reduced, some mild and transient adverse
effects were visible in two subjects. If the IV dose was increased,
more severe adverse effects might be expected. This is in line with
the unexpected sensitivity of horses to certain drugs when they are
injected IV (Jones, 1972). However, it is not clear if the adverse effects
are due to the excipients or to the active compound itself. As several
adverse effects have been reported in humans after long-term FLU
administration (Devulder, 2010), further studies involving multi-
ple drug administrations over a longer period of time are warranted
to clarify the safety of this active ingredient in the horse.
FLU is a water soluble compound in the form of maleate salt (pKa
5.3) that is rapidly absorbed from the human gastrointestinal tract
(Klawe and Maschke, 2009). The Tmax found in our study (2.16 h) is
between the Tmax reported for dogs (1.42 h) and that for humans
(range 1.6–1.8 h), and cats (2.78 h). A number of factors may be re-
sponsible for this difference including the large variation in this
parameter in the horse, different absorption due to variable disso-
lution of the drug in the stomach, or other species-specific factors.
In contrast, while the maximal plasma concentrations of FLU after
PO administration in humans (100mg/subject; Abrams et al., 1988)
and in cats (De Vito et al., 2014a) were comparable (when normal-
ized for the administered dose and F%), in horses they showed a
lower average value compared to that reported for dogs (De Vito
et al., 2014b). A large difference (about 40%) has been shown in oral
F% between humans (90%) and animals (cats and dogs). In horses,
the oral F% was 71%. Wide differences in F% between humans and
animals and between animals (carnivorous vs. herbivorous) have
previously been demonstrated, indicating that F% values derived in
one animal species cannot always be extrapolated to humans or other
animal species (Chiou et al., 2000; Kim et al., 2014, 2015).
Although FLU has been used in the treatment of acute and chronic
states in humans for 25 years, no minimal effective concentration for
pain relief has yet been reported.However, it is noteworthy that inhorses
(despite the lower oral F% than in humans) a dose of 5mg/kg PO pro-
duced FLUplasma concentrations higher that theplasma concentrations
produced by the PO clinical dose (100mg/subject/day) reported in
humans (Hlavica and Niebch, 1985). After compartmental modelling/
simulation, the calculated dose that produces Cmax and AUC values
(critical parameters for the evaluation of bioequivalence) in horses
similar to those reported to be effective in humans is 2.6mg/kg/day.
Further support for this calculation can be obtained using the FLU con-
centration at a steady state condition for the daily clinical dose in
humans. According to Abrams et al. (1988), an AUC value of 6070 μg
h/L is obtainedwith adose of 100mg in volunteers having abodyweight
of 63 kg (equivalent to 1.58mg/kg). The corresponding average plasma
concentration in steady state condition is 6070/24 h = 253 ng/mL. To
achieve the same average plasma concentration in the horse, this value
ismultiplied to account for the apparent plasma clearance in the horse
(253 ng/mL × 411mL/kg/h × 24 h = 2.5mg/kg). This dose (the equiva-
lent analgesic dose to the human clinical dose) is in line with the ED50
values experimentally calculated earlier in cats and dogs (Gordon et al.,
1987; Nickel, 1987). The drug plasma EC calculated after the simula-
tion is exceeded for over 9 h and 15 h, after 2.6 and 5mg/kg FLU oral
administration, respectively, suggesting a long lasting therapeutic
effect of the drug. It is emphasised here that both the dose and EC
are still theoretical and unconfirmed and further PK/PD studies are
required.
Following PO administration of FLU, horses showed mean ter-
minal plasma elimination half-lives in between those reported in
cats (13.6 h) and dogs (7.1 h) (De Vito et al., 2014a and b). This is
consistent with the clearance value of FLU in horses which is smaller
than that reported in dogs (604 mL/h/kg) and larger than that re-
ported in cats (195 mL/h/kg) (De Vito et al., 2014a and b). A likely
explanation for the difference in half-life values could be that in cats,
FLU is bio-transformed to the N-acetylated analogue D13223, as is
the case in humans (Methling et al., 2009); whereas this transfor-
mation could be slower or may occur to a lesser extent in horses.
Indeed, horses are well known as being poor acetylators (Toutain
et al., 2010).
Conclusions
This is the first study on FLU in horses. The pharmacokinetic pro-
files of FLU in the horse were somewhat different compared to FLU
disposition in humans, cats and dogs. Intravenous administration
is not advisable in horses because it is likely to produce adverse
effects. Although the oral F% of FLU was lower than that in humans,
a 5 mg/kg administration produced plasma concentrations exceed-
ing those reported in humans after clinical dosing. An oral dose of
2.6 mg/kg in horses has been calculated to give Cmax and AUC values
similar to those after clinical dose administration in humans. This
latter finding is however theoretical and needs to be supported with
sound experimental data. The data generated in this research could
pave the road for further studies of this active ingredient in equine
medicine in order to assess whether this drug may be suitable for
horses.
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